The DOI matches its Crossref record; 333 of the 333 references it cites were found in a registry or an index.
The delivery of therapeutic oligonucleotides
Open accessAbstract
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the approval of the first antisense drug and with promising developments in late stage clinical trials using siRNA or splice switching oligonucleotides. However, effective delivery of oligonucleotides to their intracellular sites of action remains a major issue. This review will describe the biological basis of oligonucleotide delivery including the nature of various tissue barriers and the mechanisms of cellular uptake and intracellular trafficking of oligonucleotides. It will then examine a variety of current approaches for enhancing the delivery of oligonucleotides. This includes molecular scale targeted ligand-oligonucleotide conjugates, lipid- and polymer-based nanoparticles, antibody conjugates and small molecules that improve oligonucleotide delivery. The merits and liabilities of these approaches will be discussed in the context of the underlying basic biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Rab proteins as membrane organizers
Zerial, M., & McBride, H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052055 · Cited by 3,381
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Wilschut, J. (1990) · Cited by 2,407
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Huotari, J., & Helenius, A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.286 · Cited by 2,265
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads
Douglas, S. M., Bachelet, I., & Church, G. M. (2012) · Science · doi:10.1126/science.1214081 · Cited by 2,180
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 2×
“Two important steps for optimizing the cationic lipids were (i) altering the pKa so that the lipids were almost uncharged in the circulation but became charged in the low pH endosome and (ii) using linkages that were readily biodegradable (172,173).”
BackgroundThe history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765
Lysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Henne, W. M., Buchkovich, N. J., & Emr, S. D. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.05.015 · Cited by 1,496
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Role of Rab GTPases in Membrane Traffic and Cell Physiology
Hutagalung, A. H., & Novick, P. J. (2011) · Physiological Reviews · doi:10.1152/physrev.00059.2009 · Cited by 1,460
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Challenges and opportunities for structural DNA nanotechnology
Pinheiro, A. V., Han, D., Shih, W. M., & Yan, H. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.187 · Cited by 1,292 · cited 1×
“DNA nanostructures represent an exciting new avenue for biotechnology research and development (325,326).”
BackgroundHammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration
Zhang, Y., Liu, D., Chen, X., Li, J., Li, L., Bian, Z., Sun, F., Lu, J., Yin, Y., Cai, X., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.010 · Cited by 1,195
The Landscape of long noncoding RNA classification
St. Laurent, G., Wahlestedt, C., & Kapranov, P. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.03.007 · Cited by 1,191
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,169
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Using exosomes, naturally-equipped nanocarriers, for drug delivery
Batrakova, E. V., & Kim, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.030 · Cited by 1,041
Argonaute proteins: functional insights and emerging roles
Meister, G. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3462 · Cited by 1,030
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
RNA-mediated epigenetic regulation of gene expression
Holoch, D., & Moazed, D. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3863 · Cited by 1,003
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Revealing the world of RNA interference
Mello, C. C., & Conte, D. (2004) · Nature · doi:10.1038/nature02872 · Cited by 997
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Copolovici, D. M., Langel, K., Eriste, E., & Langel, Ü. (2014) · ACS Nano · doi:10.1021/nn4057269 · Cited by 963
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948 · cited 4×
“Another interesting report demonstrated that the NPC1 lipid transport system, previously shown to be involved in LNP processing (158), is also involved in the processing of certain types of polymeric nanoparticles (227).”
BackgroundInfluentialAptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Caveolae as plasma membrane sensors, protectors and organizers
Parton, R. G., & del Pozo, M. A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3512 · Cited by 924
Properties of the Glomerular Barrier and Mechanisms of Proteinuria
Haraldsson, B., Nyström, J., & Deen, W. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00055.2006 · Cited by 909
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Scavenger receptors in homeostasis and immunity
Canton, J., Neculai, D., & Grinstein, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3515 · Cited by 838
Assembly and localization of Toll-like receptor signalling complexes
Gay, N. J., Symmons, M. F., Gangloff, M., & Bryant, C. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3713 · Cited by 832
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Synthetic genetic polymers capable of heredity and evolution
Pinheiro, V. B., Taylor, A. I., Cozens, C., Abramov, M., Renders, M., Zhang, S., Chaput, J. C., Wengel, J., Peak-Chew, S.-Y., McLaughlin, S. H., et al. (2012) · Science · doi:10.1126/science.1217622 · Cited by 730
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693
Cai, H., Reinisch, K., & Ferro-Novick, S. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.005 · Cited by 685
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Regulation of Endothelial Permeability via Paracellular and Transcellular Transport Pathways
Komarova, Y., & Malik, A. B. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135833 · Cited by 641
Mechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D'Souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 621
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Regulation of GPCRs by Endocytic Membrane Trafficking and Its Potential Implications
Hanyaloglu, A. C., & Zastrow, M. V. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094830 · Cited by 609
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Juliano, R. L. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.090401.151133 · Cited by 597
Self-citationSpherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma
Jensen, S. A., Day, E. S., Ko, C. H., Hurley, L. A., Luciano, J. P., Kouri, F. M., Merkel, T. J., Luthi, A. J., Patel, P. C., Cutler, J. I., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006839 · Cited by 592
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Folate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 585
Multivesicular Body Morphogenesis
Hanson, P. I., & Cashikar, A. (2012) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154152 · Cited by 584
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Lai, C. P., Kim, E. Y., Badr, C. E., Weissleder, R., Mempel, T. R., Tannous, B. A., & Breakefield, X. O. (2015) · Nature Communications · doi:10.1038/ncomms8029 · Cited by 574
Endosome maturation, transport and functions
Scott, C. C., Vacca, F., & Gruenberg, J. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.03.034 · Cited by 571
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.-R., Jiang, J., Watt, A. T., Chun, S., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 561
Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates
Goubau, D., Schlee, M., Deddouche, S., Pruijssers, A. J., Zillinger, T., Goldeck, M., Schuberth, C., Van der Veen, A. G., Fujimura, T., Rehwinkel, J., et al. (2014) · Nature · doi:10.1038/nature13590 · Cited by 557
ENCODE Project Writes Eulogy for Junk DNA
Pennisi, E. (2012) · Science · doi:10.1126/science.337.6099.1159 · Cited by 545
Exosomes for targeted siRNA delivery across biological barriers
EL Andaloussi, S., Lakhal, S., Mäger, I., & Wood, M. J. A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.008 · Cited by 539
Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates
Choi, C. H. J., Hao, L., Narayan, S. P., Auyeung, E., & Mirkin, C. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305804110 · Cited by 533
Targeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Clathrin-independent pathways of endocytosis
Mayor, S., Parton, R. G., & Donaldson, J. G. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016758 · Cited by 525
Organization of the ER–Golgi interface for membrane traffic control
Brandizzi, F., & Barlowe, C. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3588 · Cited by 522
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Meng, L., Ward, A. J., Chun, S., Bennett, C. F., Beaudet, A. L., & Rigo, F. (2015) · Nature · doi:10.1038/nature13975 · Cited by 518
Therapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 510
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Integrins: masters and slaves of endocytic transport
Caswell, P. T., Vadrevu, S., & Norman, J. C. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2799 · Cited by 460
G Protein–Coupled Receptor Sorting to Endosomes and Lysosomes
Marchese, A., Paing, M. M., Temple, B. R. S., & Trejo, J. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094646 · Cited by 456
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Wickner, W., & Schekman, R. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1451 · Cited by 435
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Rehman, Z. U., Hoekstra, D., & Zuhorn, I. S. (2013) · ACS Nano · doi:10.1021/nn3049494 · Cited by 395
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 395
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Lipid Rafts, Caveolae, and Their Endocytosis
(2010) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(10)82003-9 · Cited by 372
Exosome Biogenesis, Regulation, and Function in Viral Infection
Alenquer, M., & Amorim, M. (2015) · Viruses · doi:10.3390/v7092862 · Cited by 368
Shear stress and the endothelial transport barrier
Tarbell, J. M. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq146 · Cited by 365
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
Bien-Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 353
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Bobbin, M. L., & Rossi, J. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103633 · Cited by 353
Nucleic Acid Delivery: The Missing Pieces of the Puzzle?
Nguyen, J., & Szoka, F. C. (2012) · Accounts of Chemical Research · doi:10.1021/ar3000162 · Cited by 347
Eguchi, A., Meade, B. R., Chang, Y.-C., Fredrickson, C. T., Willert, K., Puri, N., & Dowdy, S. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1541 · Cited by 340
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Grozovsky, R., Begonja, A. J., Liu, K., Visner, G., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2015) · Nature Medicine · doi:10.1038/nm.3770 · Cited by 336
Mechanism Matters: A Taxonomy of Cell Penetrating Peptides
Kauffman, W. B., Fuselier, T., He, J., & Wimley, W. C. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.10.004 · Cited by 333
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
Rab GTPase regulation of membrane identity
Pfeffer, S. R. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.04.002 · Cited by 323
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321 · cited 1×
“The 2013 approval of the first major antisense drug, Kynamro R © (2), an inhibitor of apolipoprotein B expression, was accompanied by promising clinical trials involving siRNA (3) and splice switching oligonucleotides (SSOs) (4).”
BackgroundEfficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 312
Localisation and trafficking of Toll-like receptors: an important mode of regulation
McGettrick, A. F., & O’Neill, L. A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.12.002 · Cited by 307
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Mechanisms of integrin activation and trafficking
Margadant, C., Monsuur, H. N., Norman, J. C., & Sonnenberg, A. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.08.005 · Cited by 304
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Exosomes: Fundamental Biology and Roles in Cardiovascular Physiology
Ibrahim, A., & Marbán, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-104929 · Cited by 301
EL Andaloussi, S., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, I. I., Simonson, O. E., Sork, H., Ezzat, K., Copolovici, D. M., Kurrikoff, K., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1299 · Cited by 301
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Tethering the assembly of SNARE complexes
Hong, W., & Lev, S. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.006 · Cited by 296
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Nelson, C. E., Kintzing, J. R., Hanna, A., Shannon, J. M., Gupta, M. K., & Duvall, C. L. (2013) · ACS Nano · doi:10.1021/nn403325f · Cited by 293
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Inhibition of Retrograde Transport Protects Mice from Lethal Ricin Challenge
Stechmann, B., Bai, S.-K., Gobbo, E., Lopez, R., Merer, G., Pinchard, S., Panigai, L., Tenza, D., Raposo, G., Beaumelle, B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.043 · Cited by 290
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284 · cited 1×
“This approach has been especially important for therapeutic use of siRNA (164) and good accounts of current clinical trials using siRNA LNPs are found in recent reviews (10,165).”
BackgroundKoller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281
Clark, A. J., & Davis, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517048112 · Cited by 280
Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse
Liu, Y., Li, D., Liu, Z., Zhou, Y., Chu, D., Li, X., Jiang, X., Hou, D., Chen, X., Chen, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep17543 · Cited by 280
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Yang, Q., Jones, S. W., Parker, C. L., Zamboni, W. C., Bear, J. E., & Lai, S. K. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400703d · Cited by 269
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Immunomodulatory spherical nucleic acids
Radovic-Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., Walker, D. A., Halo, T. L., Merkel, T. J., Rische, C. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502850112 · Cited by 259
Microvesicle-mediated RNA Molecule Delivery System Using Monocytes/Macrophages
Akao, Y., Iio, A., Itoh, T., Noguchi, S., Itoh, Y., Ohtsuki, Y., & Naoe, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.254 · Cited by 253
Nanotoxicity: A Key Obstacle to Clinical Translation of siRNA-Based Nanomedicine
Xue, H. Y., Liu, S., & Wong, H. L. (2014) · Nanomedicine · doi:10.2217/nnm.13.204 · Cited by 250
DNA Nanostructures as Smart Drug-Delivery Vehicles and Molecular Devices
Linko, V., Ora, A., & Kostiainen, M. A. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.08.001 · Cited by 249
Intracellular Fate of Spherical Nucleic Acid Nanoparticle Conjugates
Wu, X. A., Choi, C. H. J., Zhang, C., Hao, L., & Mirkin, C. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja503010a · Cited by 245
Delivery of therapeutic oligonucleotides with cell penetrating peptides
Boisguérin, P., Deshayes, S., Gait, M. J., O'Donovan, L., Godfrey, C., Betts, C. A., Wood, M. J. A., & Lebleu, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.008 · Cited by 245
Integrin Targeted Therapeutics
Millard, M., Odde, S., & Neamati, N. (2011) · Theranostics · doi:10.7150/thno/v01p0154 · Cited by 245
Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein
Benimetskaya, L., Loike, J. D., Khaled, Z., LoiKe, G., Silverstein, S. C., Cao, L., Khoury, J. E. L., CaI, T.-Q., & Stein, C. A. (1997) · Nature Medicine · doi:10.1038/nm0497-414 · Cited by 242
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Hwang, D. W., Son, S., Jang, J., Youn, H., Lee, S., Lee, D., Lee, Y.-S., Jeong, J. M., Kim, W. J., & Lee, D. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.047 · Cited by 234
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy
Cornelio, D. B., Roesler, R., & Schwartsmann, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm058 · Cited by 234
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
Randeria, P. S., Seeger, M. A., Wang, X.-Q., Wilson, H., Shipp, D., Mirkin, C. A., & Paller, A. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505951112 · Cited by 224
Reprogramming human fibroblasts to pluripotency using modified mRNA
Mandal, P. K., & Rossi, D. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.019 · Cited by 221
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery
Lu, J. J., Langer, R., & Chen, J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900023v · Cited by 219
Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 213
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210
Future of the Particle Replication in Nonwetting Templates (PRINT) Technology
Xu, J., Wong, D. H. C., Byrne, J. D., Chen, K., Bowerman, C., & DeSimone, J. M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209145 · Cited by 208
Membrane traffic in the secretory pathway: Membrane fusion: SNAREs and regulation
Malsam, J., Kreye, S., & Söllner, T. H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8352-3 · Cited by 208
Recent advances in delivery of drug–nucleic acid combinations for cancer treatment
Li, J., Wang, Y., Zhu, Y., & Oupický, D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.010 · Cited by 207
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Zhu, X., Xu, Y., Solis, L. M., Tao, W., Wang, L., Behrens, C., Xu, X., Zhao, L., Liu, D., Wu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505629112 · Cited by 203
Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors
Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers
Thiel, K. W., Hernandez, L. I., Dassie, J. P., Thiel, W. H., Liu, X., Stockdale, K. R., Rothman, A. M., Hernandez, F. J., McNamara, J. O., & Giangrande, P. H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks294 · Cited by 202
Zheng, C., Zheng, M., Gong, P., Deng, J., Yi, H., Zhang, P., Zhang, Y., Liu, P., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.053 · Cited by 200
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery
Biswas, S., Deshpande, P. P., Navarro, G., Dodwadkar, N. S., & Torchilin, V. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.024 · Cited by 197
Tethering complexes in the endocytic pathway: CORVET and HOPS
Solinger, J. A., & Spang, A. (2013) · The FEBS Journal · doi:10.1111/febs.12151 · Cited by 197
Autophagy for tissue homeostasis and neuroprotection
Mariño, G., Madeo, F., & Kroemer, G. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.001 · Cited by 195
Meade, B. R., Gogoi, K., Hamil, A. S., Palm-Apergi, C., Berg, A. V. D., Hagopian, J. C., Springer, A. D., Eguchi, A., Kacsinta, A. D., Dowdy, C. F., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3078 · Cited by 191
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis
Yao, Y.-D., Sun, T.-M., Huang, S.-Y., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C.-Q., Yu, F.-Y., Zeng, M.-S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 188
CpG Still Rocks! Update on an Accidental Drug
Krieg, A. M. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0340 · Cited by 187
Lönnberg, H. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800406a · Cited by 187
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Liang, X.-H., Sun, H., Shen, W., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv143 · Cited by 182
Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Self-citationPolyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung
Günther, M., Lipka, J., Malek, A., Gutsch, D., Kreyling, W., & Aigner, A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.007 · Cited by 180
Aptamers and Their Applications in Nanomedicine
Sun, H., & Zu, Y. (2015) · Small · doi:10.1002/smll.201403073 · Cited by 180
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Zhang, H., Ma, Y., Xie, Y., An, Y., Huang, Y., Zhu, Z., & Yang, C. J. (2015) · Scientific Reports · doi:10.1038/srep10099 · Cited by 174
Antisense-based therapy for the treatment of spinal muscular atrophy
Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207087 · Cited by 172
Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy
Esposito, C. L., Cerchia, L., Catuogno, S., De Vita, G., Dassie, J. P., Santamaria, G., Swiderski, P., Condorelli, G., Giangrande, P. H., & de Franciscis, V. (2014) · Molecular Therapy · doi:10.1038/mt.2014.5 · Cited by 169
Oligonucleotide Conjugates for Therapeutic Applications
Winkler, J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.47 · Cited by 167
Pan, H., Liu, L., & Cai, L. (2022) · Biomaterial Engineering · doi:10.1007/978-981-16-5419-0_18 · Cited by 165
Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., Leslie, M. C., Vivas-Mejia, P. E., Lopez-Berestein, G., Sood, A. K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2397 · Cited by 163
Recent Developments in Nucleic Acid Delivery with Polyethylenimines
Neuberg, P., & Kichler, A. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800148-6.00009-2 · Cited by 161
Toxicology of antisense therapeutics
Jason, T. L. H., Koropatnick, J. D., & Berg, R. W. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.017 · Cited by 161
Goldenring, J. R. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.04.018 · Cited by 161
Mipomersen Sodium: First Global Approval
Hair, P., Cameron, F., & McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0042-2 · Cited by 160
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 160
Southwell, A. L., Skotte, N. H., Kordasiewicz, H. B., Østergaard, M. E., Watt, A. T., Carroll, J. B., Doty, C. N., Villanueva, E. B., Petoukhov, E., Vaid, K., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.153 · Cited by 158
Biswas, S., & Torchilin, V. P. (2013) · Pharmaceuticals · doi:10.3390/ph6020161 · Cited by 158
Cited by
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Metadata
- Authors
- Juliano, R. L.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-15
- Volume
- 44
- Issue
- 14
- Pages
- 6518-6548
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2336977304
- Cited by
- 854
- References
- 333
- FWCI
- 45.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.